港股异动 | 联邦制药(03933)早盘涨近3% 创新药TUL01101片II期临床达标 计划开展III期试验

Core Viewpoint - Federal Pharmaceutical (03933) has seen a nearly 3% increase in early trading, currently up 2.32% at HKD 12.8, with a trading volume of HKD 64.0646 million [1] Group 1: Clinical Research Progress - The company announced that its self-developed innovative drug TUL01101 has completed Phase II clinical trials in adult patients with moderate to severe atopic dermatitis in China [1] - TUL01101 met the expected goals in the Phase II clinical study, supporting its progression to the next stage of clinical research [1] - The company has completed communication with regulatory authorities regarding TUL01101's EOP2 and is initiating Phase III clinical trials in China for moderate to severe atopic dermatitis patients [1]